PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
32931834-5	2020	In an attempt to identify potent AChE and hCA inhibitors, new thiazolyl-pyrazolines (3a-k) were designed based on the molecular hybridization of thiazole and pyrazoline scaffolds.	thiazolyl-pyrazolines	62-83	acetylcholinesterase (Cartwright blood group)	Homo sapiens	33-37
35607598-6	2022	Furthermore, docking studies were accomplished to evaluate the patterns of binding of thiazolyl-pyrazolines 7b, 7g, 7l, and 7m in the EGFR active pocket (PDB ID: 1M17).	thiazolyl-pyrazolines	86-107	epidermal growth factor receptor	Homo sapiens	134-138
35607598-8	2022	Also, the tested thiazolyl-pyrazolines (7b, 7g, 7l, and 7m) demonstrated significant sub-micromolar EGFR inhibitory actions with IC50 values 83, 262, 171 and 305 nM, respectively, in comparison to erlotinib (IC50 =57 nM).	thiazolyl-pyrazolines	17-38	epidermal growth factor receptor	Homo sapiens	100-104
34569655-2	2021	All new thiazolyl-pyrazolines showed activity at nanomolar levels as hCA I, hCA II, and AChE inhibitors, with KI values in the range of 13.35-63.79, 7.01-115.80, and 17.89-48.05 nM, respectively.	thiazolyl-pyrazolines	8-29	carbonic anhydrase 1	Homo sapiens	69-74
34569655-2	2021	All new thiazolyl-pyrazolines showed activity at nanomolar levels as hCA I, hCA II, and AChE inhibitors, with KI values in the range of 13.35-63.79, 7.01-115.80, and 17.89-48.05 nM, respectively.	thiazolyl-pyrazolines	8-29	acetylcholinesterase (Cartwright blood group)	Homo sapiens	88-92
32931834-5	2020	In an attempt to identify potent AChE and hCA inhibitors, new thiazolyl-pyrazolines (3a-k) were designed based on the molecular hybridization of thiazole and pyrazoline scaffolds.	thiazolyl-pyrazolines	62-83	HCA1	Homo sapiens	42-45
31493743-0	2019	Design, synthesis and biological evaluation of a new series of thiazolyl-pyrazolines as dual EGFR and HER2 inhibitors.	thiazolyl-pyrazolines	63-84	epidermal growth factor receptor	Homo sapiens	93-97
31493743-0	2019	Design, synthesis and biological evaluation of a new series of thiazolyl-pyrazolines as dual EGFR and HER2 inhibitors.	thiazolyl-pyrazolines	63-84	erb-b2 receptor tyrosine kinase 2	Homo sapiens	102-106